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ABSTRACT
Background  and  the  Purpose  of  the  Study:  Oral  mucositis  is  one  of  the  most  common 
complications of malignancy chemotherapy. As yet, no absolute treatment has been demonstrated 
to be effective for chemotherapy- induced oral mucositis. This study evaluates the effectiveness 
of phenytoin mouthwash as a wound healing agent, on the basis of stimulating effects on 
fibroblast proliferation. 
Materials and Methods: In this multicenter, randomized, placebo- controlled clinical trial; 
twelve patients received phenytoin mouthwash (0.5%) or placebo for about two weeks. Oral pain 
severity was scored on the daily basis using a VAS (visual analogue scale) of 10 centimeters. 
National Cancer Institute (NCI) scale was used to grade the intensity of mucositis. To determine 
the effect of treatment, a quality of life questionnaire, consisting of 35 queries, was filled out for 
all patients. Statistical analyses of data was performed using Mann- Whitney test.
Results: The average time for complete remission of mucositis in phenytoin- treated group was 
less than that of the placebo group. The quality of life improved dramatically in the phenytoin 
group with the healing process being more evident in the first week. Furthermore, reduction in 
the wound area was greater in the phenytoin group than controls at the end of the first week 
of treatment. Both groups eventually demonstrated reduction in pain intensity; however no 
statistically significant difference was observed between two groups. 
Conclusion: Phenytoin mouthwash accelerated wound healing and resolution of mucositis and 
improved life quality impressively.
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INTRODUCTION
Destruction of oral mucosa, known as oral mucositis, 
is a result of cancer therapy with chemotherapeutic 
agents  which  typically  manifests  as  erythema, 
edema, athrophy or ulcerations of oral mucosa. The 
prevalence of oral mucositis after chemotherapy is 
15- 40% (1). It can compromise a patient’s ability to 
tolerate planned cancer therapy, and leads to missing 
or reducing doses and eventually a less successful 
prognosis. For patients being treated with the most 
common chemotherapy regimens for bone marrow 
transplant,  the  prevalence  of  oral  mucositis  may 
increase to 75-100%. .In this group of patients, oral 
mucositis  comprises  one  of  the  most  debilitating 
aspects of cancer therapy. Oral mucositis, especially 
when severe, has a major impact on the quality of life 
and daily functioning of patients (2). It can present 
different  levels  of  severity,  ranging  from  a  minor 
erythema to large and painful ulcers that limit basic 
oral functions such as swallowing, eating, drinking, 
and talking. In addition to direct complications (such 
as septicemia), oral mucositis leads indirectly to the 
elongation of hospitalization period and an increase 
in the treatment cost (1, 2) .  
A number of different strategies for the management of 
mucositis have been proposed including: debridement 
of oral lesions, oral decontamination, topical & systemic 
pain management, prophylaxis, and control of bleeding 
(1, 3) . Different methods and medical agents have 
been developed to alleviate the symptoms and combat 
oral mucositis including mouthwash solutions such 
as  alopurinol  (4),  chlorhexidine,  diphenhydramine, 
aluminium  hydroxide  and  pallifermin  (5,6). 
Unfortunately each of these agents only target limited 
and specific aspects of the condition and are ineffective 
on the other ones.
Phenytoin,  an  antiseizure  medication,  has  been 
reported to promote wound healing when applied as 
a topical agent on skin and mucosal lesions (7) . It 
has been proven to be effective on acute and chronic 
lesions  with  various  etiologies  such  as  decubitus 
ulcers, leprosy ulcers, pressure sores, diabetic ulcers 
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(8) , traumatic wounds, burns, epidermolysis bullosa 
(simplex type), aphthous ulceration, and oral lichen 
planus (9, 10) . Phenytoin promotes wound healing 
by a number of mechanisms including stimulation 
of  fibroblast  proliferation,  facilitation  of  collagen 
deposition by inhibiting the activity of collagenase 
enzymes, and antibacterial activity. Furthermore, by 
stabilizing neural fiber membranes and reducing the 
inflammatory response, phenytoin contributes to the 
topical pain relief (9, 11) .
Since  in  chemotherapy,  the  submucosal  tissue  is 
targeted  by  stomatotoxic  materials  and  fibroblasts 
apoptosis precedes the epithelial damage (12) , the 
ability of phenytoin to induce fibroblast proliferation 
and collagen deposition, makes a great contribution 
to the treatment of oral mucositis. Moreover, the side 
effects of topical phenytoin are rare and its systemic 
absorption is insignificant (9, 10) .Phenytoin appears 
to be a safe, effective, easy- to –use, and inexpensive 
treatment modality (9) . Various studies and reviews 
have  been  reported  on  the  beneficial  effects  of 
phenytoin on the treatment of skin and soft tissue 
wounds and ulcers of various types. However, little 
attention has been paid to its role in the healing of 
oral lesions. Based on our research, so far, only one 
study has specifically investigated the effect of topical 
phenytoin  on  the  healing  process  of  oral  lesions 
(aphthous  stomatitis  in  particular)  (13) .Therefore, 
areas  of  potential  research  that  may  improve  the 
current knowledge and clinical management of oral 
mucositis by topical phenytoin is merited. 
In the present study, the effectiveness of phenytoin 
mouthwash as an analgesic and wound healing agent 
on chemotherapy- induced oral mucositis have been 
assessed and compared with placebo. 
MATERIAL  AND  METHODS
This study was designed as a randomized, placebo- 
controlled  clinical  trial,  where  the  patients,  the 
nurse  who  handed  in  the  mouthwash  (phenytoin 
and placebo) to the patients, and the clinician who 
examined  the  subjects  and  recorded  the  results, 
were  all  blind  to  the  subject’s  assignment  to  trial 
groups. The study population consisted of patients 
undergoing  chemotherapy  process,  due  to  various 
types of malignancies, from December of 2006 to 
May of 2007. Patients were recruited from oncology 
department  of  Taleghani  Hospital,  and  Internal 
Medicine and oncology Wards of Naft Hospital in 
Tehran, Iran. The number of patients in treatment and 
control  groups  in  each  department  was  equalized  (2 
patients with solid tumors from departments of Internal 
Medicine, and 10 patients with blood malignancies from 
Oncology Department of Naft & Taleghani Hospitals). 
Patients  were  assigned  to  case  &  control  groups 
randomly and separately at each department. 
Sampling method was performed on a multi- central, 
non-  probable  (easy-  to-  access)  basis.  Data  were 
collected by observation and interview. The inclusion 
criteria were as follows:
Patients  undergoing  chemotherapy  without 
simultaneous  radiation  therapy;  2)  Suffering  from 
mucositis of grade 2 (erythema, edema, or painful 
lesions, but solid diet tolerated) or 3 (erythema, edema, 
and oral ulcers with need for intra- venous hydration) 
according  to  National  Cancer  Institute  (NCI) 
classification (14) ; 3) Not being affected by systemic 
diseases including oral mucositis (such as connective 
tissue diseases and Sjogren syndrome), or interference 
with healing process of tissues (such as diabetes); 4) Not 
being a heavy smoker according to WHO definition; 
5)  Having  informed  consent  of  patients  and  their 
physicians, and no interference of this treatment with 
that of the primary disease/ cancer; 6) Absence of severe 
psychological disorders, such as major depression, which 
would interfere with the research process; 7) Patient’s 
prognosis for at least 6 month is estimated.
Exclusion criteria: 1) Patient developing mucositis of 
grade 4 based on NCI grading scale; 2) Appearance 
of  treatment  side  effects  (such  as  allergy);  3)  No 
cooperation or no tendency to continue the treatment 
process on behalf of the patient.
All patients with oral mucositis due to cancer therapy 
who  met  the  inclusion  criteria  were  randomly 
classified to two groups of treatment and placebo.
Two patients were uncooperative and excluded later 
during the investigation. The remaining 12 patients 
were examined for oral mucositis, and the severity of 
the condition was scored using the NCI scale. The oral 
mucosa was divided to 7 sites on the right and 7sites 
on the left (including: vestibular and buccal mucosa, 
gingivae,  floor  of  the  mouth  &  ventral  surface  of 
the tongue, margins & dorsal surface of the tongue, 
vestibular  &  labial  mucosa,  soft  palate,  and  hard 
palate), and the score of mucositis was determined 
separately for each site. 
These evaluations were performed at three intervals: 
prior  to  the  start  of  the  study,  one  and  two  weeks 
after  beginning  of  the  study.  The  date  of  treatment 
commencement and that of mucositis termination was 
recorded, and based on these dates duration of mucositis 
was calculated. Resolution of mucositis was considered 
when there was no evidence of mucositis of grade 2 or 3 
at any site of the oral cavity.
Oral pain severity was reported on a daily basis using 
a visual analogue scale (VAS), which anchored with 
“no pain at all” and “the worst pain possible” at 0 
and 10, respectively. Until the complete resolution 
of mucositis, patients’ oral pain was recorded on 
a  separate  piece  of  paper  daily,  then  measured 
with a fine ruler on a millimeter scale and finally 
transferred to the original data forms. This effort 
was made to make the measurements as independent 
as possible in a way that the patient would not rate 
his/her pain according to what he/she had recorded 
on  the  day(s)  before.  Furthermore,  to  evaluate 
the patients’ quality of life, a persian translation of 
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been validated in former studies (15) was used. The 
questionnaire consisted of 35 queries, was completed 
at the three aforementioned intervals. For the first 30 
queries a Lickert- type scale was utilized permitting 
the patients to scale responses. 
For each question 4 answers were considered. The 
responses: “absolutely not”, “very little”, “relatively 
high”, and “very much”, were assigned scores of 1, 
2, 3, and 4 respectively. The first 16 questions were 
related to the oral signs and symptoms during the last 
week, and the next 14 queries were on private and 
social relations. The next 5 questions were designed 
in a “yes” or “no” format (score 2 and 1 respectively) 
to  evaluate  the  general  aspects  such  as  weight 
changes, use of analgesics, and nutritional status. For 
every unanswered question a score of 1 was recorded. 
Therefore, the lowest and the highest possible score 
in the quality of life questionnaire were 35 and 130 
respectively. 
Phenytoin  was  prepared  as  an  oral  rinse  at  a 
concentration  of  0.5%  (Alborz  Pharmaceutical 
Company, Tehran, Iran).  The concentration of topical 
phenytoin creams, which are applied on skin lesions, 
is  about  1%.  Considering  the  greater  mucosal 
absorption of phenytoin compared to its cutaneous 
absorption, the 0.5% concentration was chosen. 
In order to minimize the burning effect of sodium 
phenytoin (13) as well as to maximize its therapeutic 
effect, half of the phenytoin used in the oral rinse was 
soluble sodium phenytoin salt and the other half was 
phenytoin powder.
The phenytoin and placebo solutions were prepared 
in the same color and containers. Administration 
was supervised by the department nurses four times 
a day and each time patients rinsed 10 ml of the 
solution in their mouths for 1 minute (to distribute 
evenly to all parts of the oral tissues) , and then 
expectorated (to minimize the systemic absorption). 
The  treatment  was  continued  until  the  complete 
healing of oral lesions or for a maximum of two 
weeks. In this study all the ethical criteria of the 
Research Deputy of “Shaheed Beheshti University of 
Medical Sciences” were met, and the informed consent 
form was signed by all patients.
Statistical analysis of data
All  data  was  analyzed  by  SPSS  10.0  software.  To 
describe  the  qualitative  data,  simple  frequency  was 
used;  however,  the  frequency  percentage  was  not 
expressed due to the limited number of samples. Means, 
standard deviations, ranges, and variation domains were 
determined to describe the quantitative data. 
To analyze the nominal data (gender), Fisher’s exact test 
was utilized. Non- parametric statistics such as Mann- 
Whitney test was used to analyze the ranking data (grade 
of lesion) and some of those quantitative data which 
didn’t show normal distribution clearly (lesion duration 
and pain severity). 
The quantitative data which were assessed at three 
intervals  (grade  of  mucositis,  and  quality  of  life) 
were first compared with the mixed design using the 
variance analysis of repetitive quantities. The next 
relevant comparisons were drawn with the quality of 
life and the percentage of its changes, using the t- test. 
Type- 1 error (α) was considered to be equal to 0.05 
and p<α was considered statistically significant. 
RESULTS  AND  DISCUSSION
The phenytoin treatment group consisted of 3 males and 
3 females. In the control group there were 2 males and 
4 females (p~1.000; X2 = 0.343). The mean age of the 
patients in groups of treatment and control were 38.8± 
13.8 and 33.3± 14.8, respectively (p= 0.520; t= 0.666). 
At the beginning of the study, there was no significant 
statistical  difference  between  the  two  groups 
regarding mucositis severity. However, later at two 
intervals (one and two weeks after beginning of the 
study), mucositis severity in the treatment group was 
significantly  lower  than  that  of  the  control  group 
(Table 1). In fact, after two weeks there was no trace 
of the lesions in any subjects of the treatment group. 
While the median duration of the lesions lasted for 4.5 
days in the treatment group and it was  in the range 
of 3-7 days, in the control group the least amount of 
time required for healing of the lesions was 6 days 
and in two of the subjects was even longer than 14 
days. Based on Mann- Whitney test, the average 
score for the two groups of treatment and control 
were obtained to be 3.8 and 9.3 respectively, which 
Mucositis Grade
at the start of study after one week after two weeks
case control case control case control
0 0 0 1 0 6 1
1 0 0 5 1 0 3
2 2 1 0 4 0 2
3 4 5 0 1 0 0
average score1 6.0 7.0 3.9 9.1 4.0 9.0
z 0.638 2.704 2.708
p 0.523 0.007 0.074
Table 1. Patients’ mucositis grade at three intervals
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demonstrated  a  significant  statistical  difference 
(p=0.008;  z=2.661).  The  findings  suggested  that 
“mucositis duration” is a stronger, more creditable 
criterion compared to the two previous variables 
(i.e. grading of mucositis & pain severity). Since 
several  sources  had  reported  the  maximum 
duration of mucositis to be two weeks (12) , in this 
study  the  mucositis  treatment  process  was  also 
followed up for about two weeks. If the follow-up 
was  taking  longer,  the  possibility  of  significant 
differences  between  the  two  groups  would  be 
higher. For example, one of the patients of the control 
group, who did not recover from mucositis at the 
end  of  the  second  week  of  study,  stated  that  in 
previous periods he had experienced mucositis for 
about a month.
In  both  groups  patients  reported  a  drop  in  pain 
gradually (p<0.001; F=41.789) and no significant 
difference was observed between the two groups 
(p=0.529;  F=0.689).  Regarding  pain  intensity,  at 
all  intervals  no  significant  difference  was  found 
between  the  two  groups  either  (Table  2). Visual 
analogue  scale  (VAS)  has  been  known  as  one 
of  the  most  authentic  and  valuable  criterion  for 
measurement  of  the  pain  severity;  and  since  it 
is  determined  by  the  patients  it  actually  reflects 
their point of view, which is the main goal of the 
 
At the start of study after one week after two weeks
case control case control case control
Number of patients 6.0 6.0 6.0 6.0 6.0 6.0 
Mean value 5.5 6.5 1.5 3.2 0 0.4
Standard Deviation 1.5 2.9 2.4 1.2 0 0.9
Average 5.5 5.5 0.5 3 0 0
Variance Domain 3-7 3-10 0-6 1-6 0-0 0-2
Average score 1,2 6.2 6.8 5 8 5.5 6.6
z 0.328 1.467 1. 095
p 0.743 0.142 0.273
Table 2. Pain severity based on VAS (visual analogue scale, maximum of 10 centimeters) of the patients at different intervals
1= Mann- Whitney Test
2= parametric test (T- test) results (which corroborated with these results)
 
At the start of study after one week after two weeks
case control case control case control
Number of patients 6.0 6.0 6.0 6.0 6.0 6.0 
Mean value 70.2 71.8 51.7 66.8 45.5 53.7
Standard Deviation 13.8 16.0 4.8 12.8 3.7 7.9
Average 68.0 74.5 51.5 69.0 45.5 56.0
Variance Domain 57-96 45-87 47-60 45-82 41-50 40-61
t 0.193 2.718 1.906
p 0.851 0.022 0.093
Table 3.  Patients’ quality of life at different intervals
treatment. Unlike the “mucositis severity”, which 
underwent  a  dramatic  decrease  in  phenytoin 
treatment group compared to the control group, no 
significant difference was observed among patients 
of the two groups regarding the “pain severity”. 
The reason is the relatively small number of the 
sample.  Furthermore,  the  authenticity  of  VAS 
has  been  proved  only  for  measurement  of  the 
pain severity at a single trial only. Meanwhile the 
concentration of the phenytoin mouthwash (0.5%) 
may be insufficient to allow the analgesic effects of 
the drug to appear or it may be even masked.
The  patients’  quality  of  life  was  also  improved 
(p=0.002 ; F=16.348), and the difference between the 
two groups was found to be statistically significant 
(p=0.028 ; F=6.219) since life quality improvement in 
the treatment group was dramatically greater than the 
control group (Table 3). Although at the start of the 
study the difference between the life quality scores 
of the two groups was not statistically significant, 
after  the  first  week  the  situation  improved  for 
the  treatment  group  but  after  the  second  week, 
the  difference  between  the  two  groups  in  terms 
of  improvement  of  their  life  quality  was  not 
significant (Table 3). Since the patient’s quality of 
life reflects the sum of the all therapeutic effects of 
the drug, improvement of life quality after 1 week in 50 Topical phenytoin on chemotherapy- induced oral mucositis
the treatment group is indicative of the effectiveness 
of the treatment. 
Although in this study serum levels of phenytoin 
in  patients  was  not  measured,  but  the  systemic 
absorption of topical phenytoin is insignificant 
(8, 11). 
In  conclusion  Phenytoin  mouthwash  accelerated 
healing  of  mucositis  and  improved  life  quality  of 
patients of this study.
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